ASX - By Stock
|
|
Re:
Qbiotics
|
|
Alf107
|
1.2K |
407K |
1 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
1.2K
|
407K
|
1
|
|
ASX - By Stock
|
|
Re:
Qbiotics
|
|
Alf107
|
1.2K |
407K |
0 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
1.2K
|
407K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Race options thread
|
|
Alf107
|
1.0K |
290K |
19 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
1.0K
|
290K
|
19
|
|
ASX - By Stock
|
|
Re:
Qbiotics
|
|
Alf107
|
1.2K |
407K |
1 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
1.2K
|
407K
|
1
|
|
ASX - By Stock
|
|
Re:
Qbiotics
|
|
Alf107
|
1.2K |
407K |
0 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
1.2K
|
407K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
[WEBINAR REPLAY] What it takes to get a new drug to market in Australia
|
|
Alf107
|
37 |
8.6K |
1 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
37
|
8.6K
|
1
|
|
ASX - By Stock
|
CGR |
Re:
Ann: Webb Project Drilling Update
|
|
Alf107
|
303 |
84K |
0 |
24/05/24 |
24/05/24 |
ASX - By Stock
|
303
|
84K
|
0
|
|
ASX - By Stock
|
CGR |
Re:
Ann: Webb Project Drilling Update
|
|
Alf107
|
303 |
84K |
2 |
24/05/24 |
24/05/24 |
ASX - By Stock
|
303
|
84K
|
2
|
|
ASX - By Stock
|
CGR |
Re:
Ann: Webb Project Drilling Update
|
|
Alf107
|
303 |
84K |
1 |
24/05/24 |
24/05/24 |
ASX - By Stock
|
303
|
84K
|
1
|
|
ASX - By Stock
|
CGR |
Re:
Ann: Webb Project Drilling Update
|
|
Alf107
|
303 |
84K |
5 |
24/05/24 |
24/05/24 |
ASX - By Stock
|
303
|
84K
|
5
|
|
ASX - By Stock
|
CGR |
Re:
Ann: Webb Project Drilling Update
|
|
Alf107
|
303 |
84K |
2 |
24/05/24 |
24/05/24 |
ASX - By Stock
|
303
|
84K
|
2
|
|
ASX - By Stock
|
CGR |
Re:
Ann: Webb Project Drilling Update
|
|
Alf107
|
303 |
84K |
0 |
24/05/24 |
24/05/24 |
ASX - By Stock
|
303
|
84K
|
0
|
|
ASX - By Stock
|
CGR |
Re:
Ann: Webb Project Drilling Update
|
|
Alf107
|
303 |
84K |
2 |
24/05/24 |
24/05/24 |
ASX - By Stock
|
303
|
84K
|
2
|
|
ASX - By Stock
|
CGR |
Re:
Ann: Webb Project Drilling Update
|
|
Alf107
|
303 |
84K |
5 |
24/05/24 |
24/05/24 |
ASX - By Stock
|
303
|
84K
|
5
|
|
ASX - By Stock
|
CGR |
Re:
Ann: Webb Project Drilling Update
|
|
Alf107
|
303 |
84K |
8 |
24/05/24 |
24/05/24 |
ASX - By Stock
|
303
|
84K
|
8
|
|
ASX - By Stock
|
|
Re:
Qbiotics
|
|
Alf107
|
1.2K |
407K |
0 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
1.2K
|
407K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
[INTERVIEW] Breaking Barriers in Cancer Treatment: Race Oncology Pioneers a New Era with Bisantrene
|
|
Alf107
|
234 |
61K |
4 |
11/05/24 |
11/05/24 |
ASX - By Stock
|
234
|
61K
|
4
|
|
ASX - By Stock
|
RAC |
Re:
[INTERVIEW] Breaking Barriers in Cancer Treatment: Race Oncology Pioneers a New Era with Bisantrene
|
|
Alf107
|
234 |
61K |
12 |
11/05/24 |
11/05/24 |
ASX - By Stock
|
234
|
61K
|
12
|
|
ASX - By Stock
|
RAC |
Re:
[INTERVIEW] Breaking Barriers in Cancer Treatment: Race Oncology Pioneers a New Era with Bisantrene
|
|
Alf107
|
234 |
61K |
13 |
11/05/24 |
11/05/24 |
ASX - By Stock
|
234
|
61K
|
13
|
|
ASX - By Stock
|
RAC |
Re:
Race options thread
|
|
Alf107
|
1.0K |
290K |
10 |
06/05/24 |
06/05/24 |
ASX - By Stock
|
1.0K
|
290K
|
10
|
|
ASX - By Stock
|
|
Re:
Qbiotics
|
|
Alf107
|
1.2K |
407K |
3 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
1.2K
|
407K
|
3
|
|
ASX - By Stock
|
|
Re:
Qbiotics
|
|
Alf107
|
1.2K |
407K |
2 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
1.2K
|
407K
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Corporate Spotlight Advertisement.on HC
|
|
Alf107
|
37 |
11K |
13 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
37
|
11K
|
13
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
Alf107
|
21K |
7.2M |
12 |
28/04/24 |
28/04/24 |
ASX - By Stock
|
21K
|
7.2M
|
12
|
|
ASX - By Stock
|
CGR |
Re:
Ann: Completion of Ground Geophysics Enhances Targets
|
|
Alf107
|
358 |
94K |
3 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
358
|
94K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
Ann: RC220 cGMP Manufacturing Complete
|
|
Alf107
|
76 |
25K |
23 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
76
|
25K
|
23
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
Alf107
|
21K |
7.2M |
26 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
21K
|
7.2M
|
26
|
|
ASX - By Stock
|
|
Re:
Qbiotics
|
|
Alf107
|
1.2K |
407K |
3 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
1.2K
|
407K
|
3
|
|
ASX - By Stock
|
|
Re:
Qbiotics
|
|
Alf107
|
1.2K |
407K |
2 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
1.2K
|
407K
|
2
|
|
ASX - By Stock
|
|
Re:
Qbiotics
|
|
Alf107
|
1.2K |
407K |
4 |
05/01/24 |
05/01/24 |
ASX - By Stock
|
1.2K
|
407K
|
4
|
|
ASX - By Stock
|
|
Re:
Qbiotics
|
|
Alf107
|
1.2K |
407K |
2 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
1.2K
|
407K
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Application for quotation of securities - RAC
|
|
Alf107
|
113 |
26K |
2 |
16/12/23 |
16/12/23 |
ASX - By Stock
|
113
|
26K
|
2
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
Alf107
|
21K |
7.2M |
20 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
21K
|
7.2M
|
20
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Alf107
|
10K |
3.8M |
14 |
29/11/23 |
29/11/23 |
General
|
10K
|
3.8M
|
14
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Alf107
|
10K |
3.8M |
42 |
29/11/23 |
29/11/23 |
General
|
10K
|
3.8M
|
42
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Updated Strategy and Investor Presentation
|
|
Alf107
|
508 |
124K |
6 |
23/11/23 |
23/11/23 |
ASX - By Stock
|
508
|
124K
|
6
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bonus Options Prospectus
|
|
Alf107
|
226 |
54K |
7 |
22/11/23 |
22/11/23 |
ASX - By Stock
|
226
|
54K
|
7
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bonus Options Prospectus
|
|
Alf107
|
226 |
54K |
19 |
22/11/23 |
22/11/23 |
ASX - By Stock
|
226
|
54K
|
19
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Alf107
|
10K |
3.8M |
13 |
22/11/23 |
22/11/23 |
General
|
10K
|
3.8M
|
13
|
|
ASX - By Stock
|
|
Re:
Qbiotics
|
|
Alf107
|
1.2K |
407K |
2 |
17/11/23 |
17/11/23 |
ASX - By Stock
|
1.2K
|
407K
|
2
|
|
ASX - By Stock
|
|
Re:
Qbiotics
|
|
Alf107
|
1.2K |
407K |
2 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
1.2K
|
407K
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Impressive Bisantrene Phase 2 AML Clinical Results
|
|
Alf107
|
231 |
66K |
15 |
10/11/23 |
10/11/23 |
ASX - By Stock
|
231
|
66K
|
15
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Impressive Bisantrene Phase 2 AML Clinical Results
|
|
Alf107
|
231 |
66K |
7 |
10/11/23 |
10/11/23 |
ASX - By Stock
|
231
|
66K
|
7
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Impressive Bisantrene Phase 2 AML Clinical Results
|
|
Alf107
|
231 |
66K |
27 |
10/11/23 |
10/11/23 |
ASX - By Stock
|
231
|
66K
|
27
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Alf107
|
10K |
3.8M |
23 |
07/11/23 |
07/11/23 |
General
|
10K
|
3.8M
|
23
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
Alf107
|
2.1K |
718K |
21 |
09/10/23 |
09/10/23 |
ASX - By Stock
|
2.1K
|
718K
|
21
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
Alf107
|
21K |
7.2M |
4 |
25/09/23 |
25/09/23 |
ASX - By Stock
|
21K
|
7.2M
|
4
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
Alf107
|
21K |
7.2M |
5 |
25/09/23 |
25/09/23 |
ASX - By Stock
|
21K
|
7.2M
|
5
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
Alf107
|
21K |
7.2M |
16 |
25/09/23 |
25/09/23 |
ASX - By Stock
|
21K
|
7.2M
|
16
|
|
ASX - By Stock
|
RAC Biotech |
Re:
Large BUY - ex insider/ ex CSO / new consultant - Dr Tillett
|
|
Alf107
|
143 |
51K |
20 |
31/08/23 |
31/08/23 |
ASX - By Stock
|
143
|
51K
|
20
|
|